LeMaitre Vascular, Inc. (LMAT)

LeMaitre Vascular's stock has experienced positive movements due to strong financial performance and strategic announcements. As of April 9, 2026, the stock price was $112.71, a 38.53% increase from April 10, 2025. In February 2026, the stock surged by 24.4% following strong Q4 2025 results, including sales of $64.5 million and a 39% year-over-year increase in Q4 EPS to $0.68. The company also raised its quarterly cash dividend by 25% and authorized a $100 million share repurchase program. In May 2026, LeMaitre Vascular announced strong preliminary Q1 2026 results with net sales of $66.6 million and diluted EPS growth of 42%, raising its full-year 2026 guidance.

While the search results do not provide an in-depth analysis of demand seasonality, it is mentioned that historically, the second quarter (Q2) has been one of LeMaitre Vascular's strongest quarters. The company's business model suggests a relatively steady demand driven by ongoing medical needs, though specific procedure volumes could be subject to healthcare cycles or patient elective surgery trends.

LeMaitre Vascular, Inc. is a medical device company focused on designing, manufacturing, and marketing specialized products for treating peripheral vascular disease, end-stage renal disease, and cardiovascular disease, primarily serving vascular surgeons. The company's business model centers on providing single-use medical devices used in open vascular surgeries and minimally invasive procedures. Its product portfolio includes valvulotomes, carotid shunts, biologic patches like the XenoSure® patch, and embolectomy catheters, along with other surgical devices and human tissue cryopreservation services through its RestoreFlow allograft business.

LeMaitre Vascular is headquartered in Burlington, Massachusetts, USA, and has a global presence, selling directly to hospitals in 31 countries and through distributors in more than 70 countries across North America, Europe, the Middle East, Africa, and the Asia Pacific region. The company maintains operational facilities in Sulzbach, Germany; Phoenix, Arizona; St. Petersburg, Florida; Brymbo, Wales; and Tokyo, Japan, and plans to expand its direct sales operations into Poland in Q4 2026.

The search results do not contain specific information or events that have explicitly affected LeMaitre Vascular, Inc.'s brand reputation in the past year. The company's strong financial performance, consistent product innovation, and direct sales approach suggest a focus on maintaining positive relationships with vascular surgeons and hospitals.

Institutional investors are the primary shareholders of LeMaitre Vascular, holding over 90% of the company's stock. Key institutional investors include The Vanguard Group, Inc., State Street Global Advisors, Inc., and BlackRock, Inc. Insider ownership, including the founding family and company executives, accounts for a significant stake, nearly 10% as of March 2025 and 7.91% as of February 19, 2026. George W. LeMaitre, the Chairman and CEO, is a notable individual shareholder.